Each long-course A-race costs roughly three to five weeks of taper and recovery, so closely spaced A-races leave little time to build
Interpretation
No trials test race number or spacing. The estimate combines taper evidence (27 studies: 2-week taper, volume cut 41-60%, Bosquet 2007; over 158,000 recreational marathoners, disciplined 3-week taper saved 2.6%, Smyth and Lawlor 2021) with recovery data: muscle damage and inflammation still raised 5 days after an Ironman in 42 men, some markers at 19 days (Neubauer 2008); measures recovering over 2-15 days in one case (Nosaka 2010); less pronounced responses in women (Danielsson 2017, 30 participants); marathon strength still reduced at day 5-7 in 10 men (Sherman 1984). The 3-5 week figure is TriForward's inference; overreaching risk framed by Meeusen 2013.
Practical implication
Plan one or two A-races for an 8-12 hour week, space long-course A-races well apart (inference: under about 8 weeks leaves little rebuild), and use B and C races as rehearsals or training days. Recovery data are mostly from men and small samples; individual variation is large.
Sources
7 sources, independently verified.
Leukocytes, creatine kinase, myoglobin and inflammatory markers (IL-6, IL-10, hs-CRP) were all elevated immediately post-race and at day 1. By day 5 most had declined but were still significantly above baseline; by day 19, most markers had normalised, though myoglobin and hs-CRP remained slightly but significantly elevated. Low-grade systemic inflammation persists for at least 5 days, and isn't fully resolved even by 19 days on every marker.
Tracking one athlete for 15 days post-Ironman: strength recovered within 2 days, running economy and jump performance took 8 days, and VO2max took the full 15 days to return to baseline — different physiological systems clearly recover at different rates after the same race. A single-subject case study, so the specific day-counts shouldn't be read as population norms, but the staggered-recovery pattern is a useful structural finding.
Cardiac troponin T reached levels associated with heart attack diagnosis in nearly every finisher immediately post-race — a striking but expected exercise-induced finding, not a sign of actual cardiac injury. Men showed higher post-race myoglobin, creatine kinase and creatinine than women, but sex made no difference to troponin or NT-proBNP. ALT (a liver-function marker) didn't peak until roughly a week post-race, later than the other muscle-damage markers.
A 2-week taper produced a moderate performance improvement (effect size 0.59±0.33); the best-performing taper design cut volume by 41-60% using an exponential (not linear) reduction (ES 0.72±0.36), while keeping both training intensity (ES 0.33±0.14) and frequency (ES 0.35±0.17) largely maintained — all differences significant at p<0.001. The core evidence for 'cut volume hard, keep intensity' tapering.
A strict 3-week taper was associated with a median time saving of 5min 32s (2.6%) over a relaxed 1-week taper, though only 64% of runners in the dataset actually used a disciplined 2-3 week taper. Women showed a larger benefit from tapers of 3 weeks or less (strict 3-week 3.19% vs 2.38% for men); the benefit of a 4-week taper was not significant for either sex. A large observational dataset, not a controlled trial.
After a marathon, leg strength improved by day 5 but remained below pre-race levels in both groups; work capacity recovered by day 3 with complete rest but was still impaired through days 5-7 in runners doing 20-45 minutes a day at 50-60% VO2max. Small, men only, older study.
Defines a continuum: functional overreaching (recovery in several days to several weeks, then improved performance), non-functional overreaching (weeks to months), overtraining syndrome (months, possibly years). A decrease in performance is the only certain sign; no single biochemical, hormonal or immune test can diagnose these states; infections are a common confounder.